

ALASKA MEDICAID
Prior Authorization Criteria

**Cambia® (diclofenac
potassium powder
50mg)**

FDA INDICATIONS AND USAGE¹

- Cambia is a non-steroidal anti-inflammatory drug used to treat acute migraine attacks in adults 18 years of age and older.

APPROVAL CRITERIA^{1,2}

1. The patient has the diagnosis of migraine headaches with or without aura **AND;**
2. The patient is at least 18 years of age or older **AND;**
3. The patient has tried and failed at least two other NSAIDS, including diclofenac potassium tablets. If unable to swallow tablets at least one liquid NSAID must have been trialed **AND;**
4. The patient has tried and failed at least two triptans or has a contraindication to their use **AND;**
5. Cambia is not being used every day.

DENIAL CRITERIA

1. Patient does **not** have migraine diagnosis **OR;**
2. Has a known hypersensitivity to diclofenac or any of its excipients or other NSAIDS **OR;**
3. Age < 18 years.
4. The patient has **not** tried and failed at least two other NSAIDS, including diclofenac potassium tablets **OR;**
5. The patient has **not** tried and failed at least two triptans, with the exception of a contraindication **OR;**
6. Cambia **is** being used every day.

CAUTIONS¹

- NSAIDS can cause an increased risk for cardiovascular events.
- NSAIDS can cause an increased risk for gastrointestinal adverse events.

DURATION OF APPROVAL

- Initial Approval: up to 6 months
 - Reauthorization Approval: up to 12 months

QUANTITY LIMIT

- 9 – 50mg Cambia packets per month

ALASKA MEDICAID
Prior Authorization Criteria

REFERENCES / FOOTNOTES:

1. Cambia [package insert]. Newark, CA; Depomed, Inc., August 2017. Accessed July 2018.
2. Shivang Joshi, Alan M. Rapoport. Diclofenac potassium for oral solution (Cambia®) in acute management of a migraine attack: clinical evidence and practical experience. Sage Journals. 2017 Feb 2;10(4):217-226. <https://doi.org/10.1177/1756285616684494>

ALASKA MEDICAID
Prior Authorization Criteria